-+ 0.00%
-+ 0.00%
-+ 0.00%

BAUSCH HEALTH, CANADA INC. AND THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE SIGN LETTER OF INTENT FOR PUBLIC DRUG PLAN COVERAGE OF (PR)OKEDI® (RISPERIDONE FOR EXTENDED-RELEASE INJECTABLE SUSPENSION) FOR THE TREATMENT OF SCHIZOPHRENIA

Reuters·06/09/2026 12:00:10

Please log in to view news